Use of Vasopressin in Septic Shock.

The aim of this observational study is to examine real-world clinical practice regarding the use of vasopressin as a second-line vasopressor in adult patients admitted to Intensive Care Units (ICUs) with septic shock.

The study focuses on critically ill adults (≥18 years) diagnosed with septic shock and treated with norepinephrine and vasopressin.

The main research questions are:

• Does early initiation of vasopressin-defined by the norepinephrine dose at the time of introduction-reduce mortality in patients with septic shock?
• What is the impact of vasopressin as a second vasopressor on renal function and the progression of organ dysfunction in septic shock patients?

Participants will:

• Be admitted to an ICU with a diagnosis of septic shock.
• Receive vasopressin as an adjunct to norepinephrine for hemodynamic support.
• Be monitored daily throughout their ICU stay, with data collected through a dedicated REDCap system.
• Have relevant clinical data pseudonymized and incorporated into the study database for statistical analysis.